Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 17, 2011

Primary Completion Date

April 7, 2017

Study Completion Date

April 7, 2017

Conditions
Prostate Cancer
Interventions
DRUG

Ipilimumab

10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.

DRUG

Leuprolide

7.5 mg intramuscular once a month for 8 months

DRUG

Goserelin

3.6 mg subcutaneous once a month for 8 months

DRUG

Degarelix

80 mg subcutaneous once a month for 8 months

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01377389 - Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | Biotech Hunter | Biotech Hunter